Compare iShares MSCI France ETF (EWQ) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Zoetis Inc — how do they compare? iShares MSCI France ETF trades at $45.14, while Zoetis Inc trades at $77.23 (market cap $31.25B). The key difference: Zoetis Inc pays a 2.84% dividend while iShares MSCI France ETF pays none, and iShares MSCI France ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EWQ | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $156.76 |
52-Week Low | $41.43 | $71.91 |
Market Cap | — | $31.25B |
Enterprise Value | — | $38.54B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI France ETF (EWQ) is trading at $45.16, up 0.27% on the day, while exhibiting a bearish technical signal with 11 sell signals versus 6 buy signals. The fund faces headwinds from European Central Bank rate hikes and energy market volatility driven by Middle East tensions, though it offers exposure to French technology investments and a scheduled $1.09 dividend in June 2026.
Outlook remains cautious amid macroeconomic uncertainty, with investment opportunity tied to France's €13 billion tech sovereignty push and AI investments, balanced against risks from energy price shocks, potential job losses in key EU sectors, and geopolitical trade tensions that could impact European equities.
Zoetis (ZTS) trades at $77.13, up 4.12% in the last session, with a bearish technical signal from moving averages. The company reported strong 2025 results, including $9.47B revenue and $2.67B net income, with high profitability margins. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU. Cash flow improved to a positive $325M in 2025, though net cash flow is projected to decline in 2026.
The stock presents a mixed outlook: strong fundamentals and a consensus price target of $101.43 suggest upside, but legal risks and bearish technicals pose near-term headwinds. Earnings momentum is key, with Q2 2026 results critical after a Q1 miss. Institutional sentiment is cautious despite no sell ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
